Overview

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Status:
Recruiting
Trial end date:
2026-01-13
Target enrollment:
Participant gender:
Summary
This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Amgen
Pfizer
Treatments:
Cetuximab
Palbociclib